Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

RGLS

Regulus Therapeutics Inc

May 02 • 04:00PM ET

2.69

Dollar change +0.18
Percentage change 7.17	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-1.59	Insider Own	12.29%	Shs Outstand	65.47M	Perf Week	18.50%
Market Cap	176.11M	Forward P/E	-	EPS next Y	-0.61	Insider Trans	-0.32%	Shs Float	57.42M	Perf Month	3.07%
Income	-30.04M	PEG	-	EPS next Q	-0.22	Inst Own	24.86%	Short Float	10.93%	Perf Quarter	97.79%
Sales	0.00M	P/S	-	EPS this Y	67.83%	Inst Trans	6.45%	Short Ratio	1.99	Perf Half Y	122.31%
Book/sh	1.05	P/B	2.57	EPS next Y	-19.90%	ROA	-77.55%	Short Interest	6.27M	Perf Year	107.72%
Cash/sh	0.36	P/C	7.39	EPS next 5Y	39.60%	ROE	-110.27%	52W Range	1.08 - 3.79	Perf YTD	110.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	50.96%	ROI	-135.05%	52W High	-29.02%	Beta	1.65
Dividend TTM	-	Quick Ratio	2.96	Sales past 5Y	1867.07%	Gross Margin	-	52W Low	149.07%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	2.96	EPS Y/Y TTM	14.84%	Oper. Margin	0.00%	RSI (14)	59.08	Volatility	13.44% 9.30%
Employees	30	Debt/Eq	0.15	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	7.25
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	1.21%	Payout	-	Rel Volume	0.23	Prev Close	2.51
Sales Surprise	-	EPS Surprise	-0.08%	Sales Q/Q	-	Earnings	Mar 21 AMC	Avg Volume	3.15M	Price	2.69
SMA20	9.00%	SMA50	20.62%	SMA200	69.50%	Trades		Volume	709,956	Change	7.17%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Initiated	Leerink Partners	Outperform	$6
Mar-28-18	Initiated	B. Riley FBR, Inc.	Neutral	$1
Jan-05-18	Initiated	Leerink Partners	Outperform	$2
Jun-13-17	Reiterated	Chardan Capital Markets	Buy	$5 → $2.50
Mar-06-17	Reiterated	Wedbush	Outperform	$8 → $6
Jan-30-17	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-30-17	Downgrade	Needham	Buy → Hold
Dec-07-16	Reiterated	Chardan Capital Markets	Buy	$12 → $5
Nov-02-16	Reiterated	Needham	Buy	$10 → $9
Jul-25-16	Reiterated	Chardan Capital Markets	Buy	$14.50 → $12
Jun-28-16	Reiterated	Needham	Buy	$25 → $10
Jun-28-16	Reiterated	FBR Capital	Outperform	$30 → $9
Jun-28-16	Reiterated	Chardan Capital Markets	Buy	$20 → $13.50
Jun-07-16	Reiterated	Chardan Capital Markets	Buy	$15 → $20
Apr-13-16	Initiated	Chardan Capital Markets	Buy	$15
Dec-04-15	Initiated	Wells Fargo	Outperform
Jun-09-15	Initiated	Guggenheim	Buy
Apr-21-15	Resumed	FBR Capital	Outperform	$30
Nov-24-14	Initiated	Deutsche Bank	Buy	$30
Aug-07-14	Reiterated	FBR Capital	Outperform	$14 → $15

Show Previous Ratings

Apr-30-24 08:00AM	Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series (PR Newswire) -8.73%
Mar-23-24 05:33AM	Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements (GuruFocus.com)
Mar-21-24 10:53PM	RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +11.20%
04:22PM	Regulus: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates (PR Newswire)
12:09PM	Loading…
Mar-13-24 12:09PM	Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study (Zacks)
Mar-12-24 06:32AM	Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity (PR Newswire) +71.01%
06:30AM	Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jan-02-24 04:05PM	Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Nov-22-23 08:00AM	Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference (PR Newswire) -5.11%
Nov-09-23 04:32PM	Regulus: Q3 Earnings Snapshot (Associated Press Finance) -5.21%
04:05PM	Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Nov-02-23 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +9.76%
Oct-19-23 08:00AM	Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Sep-20-23 07:00AM	Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -20.61%
08:00AM	Loading…
Sep-13-23 08:00AM	Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +13.70%
Sep-05-23 08:00AM	Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences (PR Newswire) +10.60%
Aug-24-23 07:33PM	Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap? (GuruFocus.com) +17.33%
Aug-23-23 01:04PM	Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance (GuruFocus.com) +17.19%
08:00AM	Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 (PR Newswire)
Aug-08-23 04:43PM	Regulus: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Aug-02-23 08:00AM	Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
Jul-18-23 08:00AM	Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference (PR Newswire)
Jun-27-23 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +6.72%
Jun-23-23 08:00AM	Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors (PR Newswire)
Jun-20-23 08:00AM	Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital (PR Newswire) -8.67%
Jun-12-23 08:00AM	Regulus Therapeutics Strengthens Research & Development Leadership (PR Newswire) +8.15%
May-16-23 08:00AM	Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -6.45%
May-11-23 04:18PM	Regulus: Q1 Earnings Snapshot (AP Finance) +15.33%
04:05PM	Loading…
04:05PM	Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates (PR Newswire)
Apr-13-23 08:00AM	Regulus Therapeutics Announces $15 Million Private Placement of Equity (PR Newswire) +35.54%
Apr-12-23 04:05PM	Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -6.24%
Mar-23-23 04:52PM	Regulus: Q4 Earnings Snapshot (AP Finance)
04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates (PR Newswire)
Feb-09-23 08:00AM	Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference (PR Newswire)
Jan-13-23 04:05PM	Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.70%
Jan-09-23 06:01AM	Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics (Benzinga)
Dec-12-22 08:00AM	Regulus Therapeutics Announces Resignation of Board Member (PR Newswire) +8.70%
Nov-29-22 05:43PM	13 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
08:00AM	Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations (PR Newswire)
Nov-10-22 04:05PM	Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates (PR Newswire)
Nov-03-22 08:00AM	Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call (PR Newswire) -5.52%
Nov-02-22 08:00AM	Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) -8.07%
Sep-13-22 11:58AM	Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study (Zacks) +10.31%
Sep-12-22 11:14AM	Regulus Shares Surge After Early-Stage RGLS8429 Data In Rare Kidney Disease (Benzinga) +15.48%
08:00AM	Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Sep-02-22 04:05PM	Regulus Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire) +5.19%
Aug-11-22 04:10PM	Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates (PR Newswire)
Aug-04-22 08:00AM	Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call (PR Newswire) +14.09%
Jun-21-22 08:00AM	Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jun-13-22 08:00AM	Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire)
Jun-02-22 08:00AM	Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK (PR Newswire)
May-17-22 04:30PM	Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference (PR Newswire) +6.56%
07:00AM	7 Penny Stocks With 10x Potential This Year (InvestorPlace)
May-12-22 04:05PM	Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates (PR Newswire) -7.67%
10:20AM	Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug (Zacks)
May-11-22 08:00AM	Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PR Newswire) +54.83%
May-05-22 04:05PM	Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call (PR Newswire) -6.41%
Mar-24-22 12:03PM	Regulus Starts Preclinical Studies In ALS Under Pact With Brigham and Women's Hospital (Benzinga)
08:00AM	Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital (PR Newswire)
Mar-10-22 04:05PM	Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates (PR Newswire)
Mar-03-22 05:15PM	Regulus Therapeutics Announces Timing for Fourth Quarter and Year-End 2021 Financial Results Webcast and Conference Call (PR Newswire) -5.28%
Feb-24-22 08:00AM	Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome (PR Newswire)
Feb-10-22 04:30PM	Regulus Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (PR Newswire)
Jan-26-22 10:00AM	Regulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jan-20-22 05:18PM	Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429 (PR Newswire)
Jan-19-22 09:38AM	Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ... (GuruFocus.com) -7.83%
Jan-04-22 08:00AM	Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference (PR Newswire)
Dec-03-21 08:30AM	Regulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development (PR Newswire) -6.85%
Dec-01-21 08:30AM	Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit (PR Newswire) -6.55%
Nov-30-21 05:23PM	Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity (PR Newswire)
Nov-24-21 04:05PM	Regulus Therapeutics Announces Private Placement of Equity (PR Newswire) +8.68%
Nov-10-21 05:45PM	Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.58%
04:05PM	Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates (PR Newswire)
Nov-03-21 05:15PM	Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call (PR Newswire)
Oct-28-21 03:05PM	Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-13-21 03:11PM	Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher (Benzinga) -29.88%
12:27PM	Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge (Benzinga)
07:27AM	20 Stocks Moving in Wednesday's Pre-Market Session (Benzinga)
Oct-12-21 04:05PM	Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease (PR Newswire)
Sep-30-21 04:45PM	Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Science (PR Newswire)
Sep-09-21 04:40PM	Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Sep-06-21 02:33PM	Is Regulus Therapeutics (NASDAQ:RGLS) Using Too Much Debt? (Simply Wall St.)
Aug-10-21 05:55PM	Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates (PR Newswire)
Aug-03-21 05:15PM	Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call (PR Newswire)
Jun-30-21 09:33AM	Is Regulus Therapeutics Inc (RGLS) A Good Stock To Buy? (Insider Monkey)
Jun-25-21 01:38PM	Regulus Therapeutics Presents Additional Data From Rare Kidney Disease Program (Benzinga) -8.50%
07:05AM	Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 (PR Newswire)
Jun-21-21 07:00AM	Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 (PR Newswire) +13.20%
Jun-11-21 08:56AM	Do Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't? (Zacks)
May-21-21 10:47AM	Regulus's Polycystic Kidney Disease Candidate Shows Benefit At Interim Analysis (Benzinga)
08:07AM	Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program (PR Newswire)
May-14-21 04:07PM	Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit (PR Newswire) +7.32%
May-13-21 05:35PM	Regulus (RGLS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:07PM	Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent Updates (PR Newswire)
03:15PM	Regulus Therapeutics, Inc. to Host Earnings Call (ACCESSWIRE)
May-06-21 03:01PM	Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) -8.74%
May-03-21 09:25AM	Regulus Therapeutics' RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker Study (Benzinga) -19.42%

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hagan Joseph P	Chief Executive Officer	Jan 18 '24	Sale	1.19	14,580	17,359	57,112	Jan 18 08:22 PM
CALSADA CRISPINA	Chief Financial Officer	Jan 18 '24	Sale	1.19	5,468	6,510	5,782	Jan 18 08:24 PM
Aker Christopher Ray	Sr. VP & General Counsel	Jan 18 '24	Sale	1.19	5,468	6,510	10,056	Jan 18 08:23 PM

Open in Screener

AUPH

Aurinia Pharmaceuticals Inc

May 02 • 04:00PM ET

5.17

Dollar change -0.03
Percentage change -0.58	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

AUPH Aurinia Pharmaceuticals Inc daily Stock Chart

Held by: IWM IWO IBB VTWO VHT VTWG SBIO VT PRFZ FHLC

Index	RUT	P/E	-	EPS (ttm)	-0.44	Insider Own	11.59%	Shs Outstand	143.83M	Perf Week	6.16%
Market Cap	739.41M	Forward P/E	10.37	EPS next Y	0.50	Insider Trans	-1.92%	Shs Float	126.45M	Perf Month	-0.19%
Income	-62.56M	PEG	-	EPS next Q	0.01	Inst Own	36.34%	Short Float	9.01%	Perf Quarter	-33.12%
Sales	191.41M	P/S	3.86	EPS this Y	111.73%	Inst Trans	8.87%	Short Ratio	5.37	Perf Half Y	-29.56%
Book/sh	2.50	P/B	2.07	EPS next Y	686.85%	ROA	-12.92%	Short Interest	11.39M	Perf Year	-55.35%
Cash/sh	2.24	P/C	2.31	EPS next 5Y	-	ROE	-16.69%	52W Range	4.71 - 12.43	Perf YTD	-42.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.35%	ROI	-14.44%	52W High	-58.41%	Beta	1.42
Dividend TTM	-	Quick Ratio	5.05	Sales past 5Y	3168.98%	Gross Margin	88.59%	52W Low	9.77%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	5.60	EPS Y/Y TTM	28.51%	Oper. Margin	-47.47%	RSI (14)	51.66	Volatility	6.00% 4.14%
Employees	300	Debt/Eq	0.25	Sales Y/Y TTM	30.37%	Profit Margin	-32.69%	Recom	1.75	Target Price	10.14
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	59.39%	Payout	-	Rel Volume	1.64	Prev Close	5.20
Sales Surprise	6.86%	EPS Surprise	48.79%	Sales Q/Q	46.19%	Earnings	May 02 BMO	Avg Volume	2.12M	Price	5.17
SMA20	2.99%	SMA50	-1.44%	SMA200	-33.63%	Trades		Volume	3,438,271	Change	-0.58%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight	$34 → $25
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform	$33 → $31
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform	$32
Jan-25-21	Reiterated	H.C. Wainwright	Buy	$30 → $35
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$34 → $28
Jun-17-20	Initiated	BTIG Research	Buy	$20
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy	$27
Dec-16-19	Reiterated	H.C. Wainwright	Buy	$25 → $32
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight	$14 → $16
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$9
Oct-30-17	Reiterated	H.C. Wainwright	Buy	$10 → $12
May-18-17	Reiterated	H.C. Wainwright	Buy	$12 → $10
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight	$14
Mar-22-17	Reiterated	FBR & Co.	Outperform	$9 → $11
Dec-30-16	Reiterated	H.C. Wainwright	Buy	$10 → $8
Aug-17-16	Reiterated	H.C. Wainwright	Buy	$7 → $10
Jun-30-16	Initiated	H.C. Wainwright	Buy	$7
May-08-15	Initiated	MLV & Co	Buy	$9

Show Previous Ratings

May-02-24 10:56AM	AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:10AM	Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:10AM	Aurinia: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results (Business Wire)
May-01-24 06:00AM	Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month (Business Wire)
06:00AM	Loading…
Apr-30-24 06:00AM	The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program (Business Wire)
Apr-16-24 10:48AM	UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire)
Apr-15-24 06:00AM	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 (Business Wire)
Apr-09-24 06:00AM	Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-29-24 08:30AM	Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program (Business Wire)
Feb-27-24 08:30AM	Aurinia to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Feb-16-24 09:22AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-15-24 07:25AM	Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -24.47%
06:49AM	Aurinia Pharmaceuticals Inc (AUPH) Announces Year-End Financial Results and Strategic Initiatives (GuruFocus.com)
06:32AM	Loading…
06:32AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:19AM	UPDATE 2-Aurinia Pharma fails to sell itself; to stop trials, cut jobs, buy back shares (Reuters)
06:10AM	Aurinia to cut research after sale process fails to find a buyer (BioPharma Dive)
06:07AM	Aurinia to stop R&D on immunotherapies to focus on kidney disease drug (Reuters)
06:00AM	Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value (Business Wire)
Feb-08-24 10:00AM	Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-05-24 08:30AM	Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024 (Business Wire)
Jan-18-24 04:30PM	Kane Biotech Announces Special Meeting of Shareholders (GlobeNewswire)
Jan-05-24 06:00AM	Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results (Business Wire)
Dec-28-23 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
Dec-20-23 06:00AM	Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 (Business Wire) -6.11%
Dec-10-23 06:59AM	This Small Pharma Could Be Targeted, But Would Be Fine Alone, Too (TheStreet.com)
Nov-23-23 09:55AM	Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-20-23 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks) +7.44%
Nov-13-23 06:00AM	Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan (Business Wire)
10:30AM	Loading…
Nov-07-23 10:30AM	Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS (voclosporin) for Patients with Lupus Nephritis at ACR 2023 (Business Wire)
09:55AM	Wall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High? (Zacks)
Nov-03-23 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
08:46AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 06:00PM	Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS for Managing Lupus Nephritis (Business Wire) +10.52%
07:50AM	Aurinia Pharmaceuticals Inc (AUPH) Reports 60% Increase in Q3 Net Product Revenue (GuruFocus.com)
07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:10AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results (Business Wire)
Oct-26-23 03:00PM	Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis (Business Wire)
Oct-19-23 10:31AM	CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 (Business Wire)
06:00AM	Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 (Business Wire)
Oct-16-23 09:29AM	Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls (Zacks) +5.32%
Oct-14-23 01:15PM	13 Stocks to Buy with Exponential Growth (Insider Monkey)
Oct-13-23 12:00PM	Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR) (Business Wire)
Oct-12-23 12:13PM	Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study (Zacks)
Oct-11-23 10:15AM	Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit (Zacks)
Oct-09-23 11:10AM	J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC (Zacks)
Oct-06-23 09:24AM	AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker (Zacks)
Oct-04-23 08:17AM	AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M (Zacks)
Oct-03-23 07:43AM	Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection (Zacks)
Sep-29-23 09:40AM	Are Medical Stocks Lagging Align Technology (ALGN) This Year? (Zacks)
Sep-27-23 09:34AM	Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)? (Zacks)
Sep-26-23 10:56AM	AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL (Zacks)
Sep-21-23 06:00AM	Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital (Business Wire)
Sep-18-23 08:52AM	5 Stocks to Buy as Drug Industry Displays Strong Fundamentals (Zacks)
Sep-06-23 09:55AM	Wall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a Bet (Zacks)
Aug-25-23 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-21-23 06:00AM	Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines (Business Wire)
Aug-03-23 07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:11AM	Aurinia: Q2 Earnings Snapshot (AP Finance)
06:00AM	Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results (Business Wire)
Jul-27-23 07:41AM	Institutions own 42% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares but individual investors control 56% of the company (Simply Wall St.)
Jul-20-23 06:00AM	Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023 (Business Wire)
Jul-19-23 12:05PM	Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events (Business Wire)
Jul-18-23 10:55AM	Aurinia Pharmaceuticals Stock Returns To A Rising Relative Strength (Investor's Business Daily)
Jul-11-23 10:55AM	Aurinia Pharmaceuticals Stock Shows Rising Relative Strength (Investor's Business Daily) +6.24%
Jul-03-23 10:42AM	Aurinia (AUPH) Up on Paving the Way for a Potential Buyout (Zacks)
Jul-02-23 05:59PM	Aurinia (AUPH) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jun-30-23 04:02PM	Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout (Investor's Business Daily) +5.68%
02:49PM	Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday (Motley Fool)
Jun-29-23 04:05PM	Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value (Business Wire)
Jun-20-23 09:00AM	Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy (Business Wire)
Jun-06-23 08:11AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +5.35%
Jun-01-23 09:00AM	LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone (Business Wire)
May-26-23 05:16PM	Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees (Business Wire)
May-23-23 06:56AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shift From Loss To Profit (Simply Wall St.)
May-17-23 12:14PM	Aurinia Announces 2023 Annual General Meeting Results (Business Wire)
May-11-23 12:00PM	Here's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to Buy (Zacks)
May-09-23 06:02AM	News Flash: Analysts Just Made A Sizeable Upgrade To Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Forecasts (Simply Wall St.)
06:00AM	Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference (Business Wire)
May-04-23 07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:11AM	Aurinia: Q1 Earnings Snapshot (AP Finance)
06:00AM	Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results (Business Wire)
May-03-23 07:51AM	Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis (Business Wire)
May-02-23 04:36PM	ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual General Meeting (Business Wire)
12:00PM	Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin) (Business Wire)
Apr-28-23 06:30AM	Glass Lewis Recommends Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual Meeting (Business Wire)
Apr-26-23 11:30AM	3 Biotechs That Might Get Bought Out in 2023 (Motley Fool)
Apr-25-23 11:00AM	Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys (Business Wire)
Apr-24-23 05:10PM	Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday (Benzinga)
06:00AM	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023 (Business Wire)
Apr-12-23 12:34PM	Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent (Zacks)
Apr-11-23 02:41PM	Why Aurinia Pharmaceuticals Stock Is Glowing Green Today (Motley Fool) +10.84%
10:26AM	Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office (Business Wire)
05:39AM	3 Stocks That Already Doubled in 2023 and Could Keep Climbing (Motley Fool)
Apr-05-23 06:30AM	Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial (Business Wire)
Apr-04-23 06:42AM	We Think Aurinia Pharmaceuticals (NASDAQ:AUPH) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Apr-03-23 04:00PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.84%
Mar-27-23 04:52AM	Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains? (Zacks)

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Greenleaf Peter	Chief Executive Officer	Mar 06 '24	Sale	5.60	126,981	711,094	1,522,114	Mar 07 04:46 PM
Robertson Stephen P.	EVP, General Counsel	Mar 06 '24	Sale	5.60	57,745	323,372	443,824	Mar 07 04:41 PM
Donley Matthew Maxwell	EVP, Ops & Strategy	Mar 06 '24	Sale	5.51	40,665	224,064	584,072	Mar 07 04:43 PM
Miller Joseph M	Chief Financial Officer	Mar 06 '24	Sale	5.60	34,811	194,942	495,928	Mar 07 04:44 PM
Habig Scott Michael	Chief Commercial Officer	Mar 06 '24	Sale	5.60	17,777	99,551	474,587	Mar 07 04:42 PM
Knappertz Volker	EVP, Research and Development	Feb 27 '24	Sale	6.10	4,930	30,073	319,128	Feb 29 04:11 PM
Knappertz Volker	EVP, Research and Development	Feb 20 '24	Sale	5.48	25,146	137,800	324,058	Feb 22 04:35 PM
Habig Scott Michael	Chief Commercial Officer	Feb 20 '24	Sale	5.48	15,867	86,951	492,364	Feb 22 04:33 PM
Jayne David R.W.	Director	May 23 '23	Sale	11.26	8,733	98,334	49,310	May 23 05:19 PM
MacKay-Dunn R. Hector	Director	May 23 '23	Sale	11.26	4,818	54,251	24,225	May 23 05:16 PM
Leversage Jill	Director	May 23 '23	Sale	11.26	4,815	54,217	18,528	May 23 05:14 PM
Billen Daniel	Director	May 23 '23	Sale	11.26	4,650	52,359	33,393	May 23 05:17 PM
Hagan Joseph P	Director	May 19 '23	Sale	10.58	272	2,878	11,961	May 23 05:18 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

RGLS

Regulus Therapeutics Inc

AUPH

Aurinia Pharmaceuticals Inc

Upgrade your FINVIZ experience